logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
K

Kevin Kalinsky

winship cancer institute of emory university
H指数:36
被引数:4,167

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

¡Mi Vida Saludable!: Results of a Randomized, Controlled, 2x2 Factorial Trial of an In-Person and eHealth Diet and Physical Activity Intervention in Latina Breast Cancer Survivors

¡Mi Vida Saludable!: 2×2析因随机对照试验的结果——一项针对拉丁裔乳腺癌幸存者的面对面及电子健康饮食和身体活动干预研究

Journal of the Academy of Nutrition and Dietetics
IF4
2025-12-130
OAAI
Heather Greenlee; Margarita Santiago-Torres; Isobel Contento; Pamela A. Koch; Eileen Rillamas-Sun; Heewon L. Gray; Adam M. Brickman; Ann Ogden Gaffney; Cynthia A. Thomson; Tracy E. Crane; Naxielly Dominguez; Jhack Sepulveda; Amanda M. Marín-Chollom; Rachel Paul; Zaixing Shi; Kathleene T. Ulanday; Melissa Accordino; Fernando J. Camacho; Katherine D. Crew; Kevin Kalinsky
Safety overview and management of inavolisib alone and in combination therapies in PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer (GO39374)

安全性概述及inavolisib单药和联合疗法在PIK3CA突变、HR阳性、HER2阴性晚期乳腺癌中的管理（GO39374）

ESMO Open
IF8.3
2025-07-010
PRE
V. Gambardella; M.K. Accordino; P.L. Bedard; A. Cervantes; E. Hamilton; A. Italiano; K. Kalinsky; I.E. Krop; M. Oliveira; C. Saura; P. Schmid; N.C. Turner; A. Varga; A. Fernandez-Saranillo; Y. Jin; S. Royer-Joo; U. Peters; N. Shankar; J.L. Schutzman; D. Juric; K.L. Jhaveri
The association of high body mass index with the safety and efficacy of sacituzumab govitecan in patients with metastatic triple-negative breast cancer from the ASCENT study

ASCENT研究中，体重指数与转移性三阴性乳腺癌患者中sacituzumab govitecan的安全性和有效性之间的关联

ESMO Open
IF8.3
2025-06-010
OA
L. García-Estévez; A. Bardia; H.S. Rugo; L.A. Carey; V.C. Diéras; S. Loibl; M. Piccart; L. Gianni; K. Kalinsky; J. O’Shaughnessy; S.A. Hurvitz; E. Harting; T. Valdez; S. Phan; C. Lai; J. Cortés
Efficacy, safety, and patient-reported outcomes across young to older age groups of patients with HR+/HER2-advanced breast cancer treated with ribociclib plus endocrine therapy in the randomized MONALEESA-2,-3, and-7 trials

在随机MONALEESA-2、-3和-7试验中，接受Ribociclib联合内分泌治疗的HR+/HER2-晚期乳腺癌患者，其疗效、安全性及患者报告结局在年轻至老年年龄组间的情况。

EUROPEAN JOURNAL OF CANCER
IF7.1
2025-02-010
PRE
Hart, Lowell L.; Im, Seock-Ah; Tolaney, Sara M.; Campone, Mario; Pluard, Timothy; Sousa, Berta; Freyer, Gilles; Decker, Thomas; Kalinsky, Kevin; Sopher, Gary; Gao, Melissa; Hu, Huilin; Kuemmel, Sherko
Comprehensive genomic profiling of ESR1, PIK3CA, AKT1, and PTEN in HR(+)HER2(-) metastatic breast cancer: prevalence along treatment course and predictive value for endocrine therapy resistance in real-world practice (June, 10.1007/s10549-024-07427-2, 2024)
BREAST CANCER RESEARCH AND TREATMENT
IF3
2024-07-130
OAAI
Bhave, Manali A.; Quintanilha, Julia C. F.; Tukachinsky, Hanna; Li, Gerald; Scott, Takara; Ross, Jeffrey S.; Pasquina, Lincoln; Huang, Richard S. P.; McArthur, Heather; Levy, Mia A.; Graf, Ryon P.; Kalinsky, Kevin
Real-world use patterns, effectiveness, and tolerability of sacituzumab govitecan for second-line and later-line treatment of metastatic triple-negative breast cancer in the United States

sacituzumab govitecan在美国转移性三阴性乳腺癌二线和后线治疗中的实际使用模式，有效性和耐受性

BREAST CANCER RESEARCH AND TREATMENT
IF3
2024-06-213
OAAI
Kalinsky, Kevin; Spring, Laura; Yam, Clinton; Bhave, Manali Ajay; Ntalla, Ioanna; Lai, Catherine; Sjekloca, Nikoleta; Stwalley, Brian; Stokes, Michael; Taylor, Aliki; Nanda, Rita
Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer (vol 8, 98, 2022)

sacituzumab govitecan治疗转移性三阴性乳腺癌的3期ASCENT试验的安全性分析 (第8、98、2022卷)

NPJ BREAST CANCER
IF7.6
2024-06-060
OAAI
Rugo, Hope S.; Tolaney, Sara M.; Loirat, Delphine; Punie, Kevin; Bardia, Aditya; Hurvitz, Sara A.; O'Shaughnessy, Joyce; Cortes, Javier; Dieras, Veronique; Carey, Lisa A.; Gianni, Luca; Piccart, Martine J.; Loibl, Sibylle; Goldenberg, David M.; Hong, Quan; Olivo, Martin; Itri, Loretta M.; Kalinsky, Kevin

研究方向

暂未获取到该数据
D
Dawn L. Hershman
H 指数:103论文数:1,247被引数:4.2万
K
Katherine D. Crew
H 指数:46论文数:419被引数:8,927
H
Heather Greenlee
H 指数:47论文数:254被引数:8,432
A
Aditya Bardia
H 指数:86论文数:1,148被引数:3.8万
M
Meghna S. Trivedi
H 指数:21论文数:143被引数:1,439
H
Hope S. Rugo
H 指数:137论文数:1,617被引数:10.1万
M
Melissa Accordino
H 指数:26论文数:306被引数:2,272
E
Erika Hamilton
H 指数:58论文数:843被引数:1.6万
M
Matthew Maurer
H 指数:25论文数:117被引数:4,424
M
Manali Bhave
H 指数:12论文数:79被引数:849